Member of FDA’s expert panel resigns over controversial Alzheimer’s therapy approval

Following the Food and Drug Administration’s polarizing authorization of the Alzheimer’s therapy Aduhelm on Monday, a member of an agency advisory committee that recommended against the drug’s approval has resigned.